MohammadHossein MozafaryBazargany
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
MohammadHossein MozafaryBazargany has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Amir Azimi
Rajaie Cardiovascular Medical and Research Institute School of Medicine Tehran Iran
2 shared publications- Ehsan Khalilipur
Rajaie Cardiovascular Medical and Research Center, Tehran, Iran (the Islamic Republic of)
2 shared publications Akram Zakani
Cardiovascular Research Center of Rajaei Alborz University of Medical Sciences Karaj 3197635141 Iran
1 shared publication- Alireza Salmanipour
Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran 1995614331, Iran
1 shared publication Amineh Safairad
Cardiovascular Intervention Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran
1 shared publicationArmin Elahifar
Cardiovascular Intervention Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Cardiology Research and Practice
- Vol. 2026 (1)
The Trace of c.3747_3748insGG Variation of the MYBPC3 Gene in the Family With Atrioventricular Canal Defect
Background: Atrioventricular canal defect (AVCD) is a congenital heart disease often associated with genetic changes, with a broad spectrum of anatomical patterns. Aim: We present a novel likely pathogenic variant of MYBPC3 in a proband with AVCD. Methods: A clinical and genetic evaluation was conducted on a one‐year‐old Iranian girl referred to our center with cardiac structural abnormalities and her family. Transthoracic echocardiography (TTE) and cardiac computed tomography (CT) were employed for clinical evaluation, and whole exome sequencing (WES), polymerase chain reaction (PCR), and Sanger sequencing were utilized for genetic analysis. Results: TTE revealed a ventricular and atrial septal defect (ASD), along with pulmonary hypertension (PH). The proband was diagnosed with AVCD through cardiac CT. WES identified a novel heterozygous MYBPC3 (NM_000256.3): c.3747_3748insGG; p.(Ile1250Glyfs∗82). Segregation analysis confirmed the presence of the same variant in the proband’s father, who was diagnosed with hypertrophic cardiomyopathy (HCM). Conclusion: We presented the first case of AVCD associated with a novel MYBPC3 variant, expanding the spectrum of cardiac anomalies linked to MYBPC3 mutations. The findings highlight the complexity and variable expression of MYBPC3 within affected family members.
- 1 January 2026
- Published by Wiley in Cardiology Research and Practice
- Vol. 2026 (1)
Open AccessThe Trace of c.3747_3748insGG Variation of the MYBPC3 Gene in the Family With Atrioventricular Canal Defect
Background: Atrioventricular canal defect (AVCD) is a congenital heart disease often associated with genetic changes, with a broad spectrum of anatomical patterns. Aim: We present a novel likely pathogenic variant of MYBPC3 in a proband with AVCD. Methods: A clinical and genetic evaluation was conducted on a one‐year‐old Iranian girl referred to our center with cardiac structural abnormalities and her family. Transthoracic echocardiography (TTE) and cardiac computed tomography (CT) were employed for clinical evaluation, and whole exome sequencing (WES), polymerase chain reaction (PCR), and Sanger sequencing were utilized for genetic analysis. Results: TTE revealed a ventricular and atrial septal defect (ASD), along with pulmonary hypertension (PH). The proband was diagnosed with AVCD through cardiac CT. WES identified a novel heterozygous MYBPC3 (NM_000256.3): c.3747_3748insGG; p.(Ile1250Glyfs∗82). Segregation analysis confirmed the presence of the same variant in the proband’s father, who was diagnosed with hypertrophic cardiomyopathy (HCM). Conclusion: We presented the first case of AVCD associated with a novel MYBPC3 variant, expanding the spectrum of cardiac anomalies linked to MYBPC3 mutations. The findings highlight the complexity and variable expression of MYBPC3 within affected family members.
- Open Access
- 26 May 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (5) , e70808
Single‐Center Evaluation of the Myval Balloon‐Expandable Transcatheter Heart Valve: A Follow‐Up Study: A Retrospective Cohort Study
Background and Aims: Our objective is to report our single‐center experience with the novel balloon‐expandable Myval Transcatheter Heart Valve (THV) system in Transcatheter Aortic Valve Replacement (TAVR) procedures. Methods: We conducted a retrospective study on a cohort of consecutive patients who underwent TAVR utilizing Myval THV from September 2021 to August 2023 at a tertiary care cardiac center. We collected baseline characteristics, pre‐ and post‐procedural echocardiographic findings, procedural details, in‐hospital outcomes, VARC‐3 technical success, and complications. Additionally, patients were followed up for 3 months concerning their clinical outcomes. Results: The study population comprised 92 TAVR patients with a mean age of 76.8 ± 7.3 years, 66.3% were male, and the mean STS score was 5.9 ± 3.2%. The most common valve sizes used were 24.5 mm (30.4%), 23 mm (26.1%), and 27.5 mm (17.4%). Pre‐dilation was performed in 32 cases (34.8%), achieving a 93.5% technical success rate. In‐hospital mortality occurred in three patients (3.3%), which included one annulus rupture. Permanent pacemaker implantation was required in six patients (6.5%). Three patients (3.3%) exhibited 3+ paravalvular leakage demonstrated by angiography. The New York Heart Association (NYHA) functional class showed significant improvement from baseline to discharge ( p < 0.0001). At the 3‐month follow‐up, five patients encountered mortality (5.4), and three experienced an episode of stroke or transient ischemic attack (3.2%). Two other patients were hospitalized due to cardiovascular events during the 3‐month follow‐up. Conclusion: The Myval THV shows a favorable safety and efficacy profile in TAVR, with low mortality and complications at 3 months.
- 26 May 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (5) , e70808
Open AccessSingle‐Center Evaluation of the Myval Balloon‐Expandable Transcatheter Heart Valve: A Follow‐Up Study: A Retrospective Cohort Study
Background and Aims: Our objective is to report our single‐center experience with the novel balloon‐expandable Myval Transcatheter Heart Valve (THV) system in Transcatheter Aortic Valve Replacement (TAVR) procedures. Methods: We conducted a retrospective study on a cohort of consecutive patients who underwent TAVR utilizing Myval THV from September 2021 to August 2023 at a tertiary care cardiac center. We collected baseline characteristics, pre‐ and post‐procedural echocardiographic findings, procedural details, in‐hospital outcomes, VARC‐3 technical success, and complications. Additionally, patients were followed up for 3 months concerning their clinical outcomes. Results: The study population comprised 92 TAVR patients with a mean age of 76.8 ± 7.3 years, 66.3% were male, and the mean STS score was 5.9 ± 3.2%. The most common valve sizes used were 24.5 mm (30.4%), 23 mm (26.1%), and 27.5 mm (17.4%). Pre‐dilation was performed in 32 cases (34.8%), achieving a 93.5% technical success rate. In‐hospital mortality occurred in three patients (3.3%), which included one annulus rupture. Permanent pacemaker implantation was required in six patients (6.5%). Three patients (3.3%) exhibited 3+ paravalvular leakage demonstrated by angiography. The New York Heart Association (NYHA) functional class showed significant improvement from baseline to discharge ( p < 0.0001). At the 3‐month follow‐up, five patients encountered mortality (5.4), and three experienced an episode of stroke or transient ischemic attack (3.2%). Two other patients were hospitalized due to cardiovascular events during the 3‐month follow‐up. Conclusion: The Myval THV shows a favorable safety and efficacy profile in TAVR, with low mortality and complications at 3 months.
- 16 January 2025
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 80 (2) , 109-114
Predictive value of inflammatory indices for one year outcome of primary percutaneous coronary intervention on saphenous vein graft in post-coronary artery bypass grafting patients
This study aims to evaluate the prognostic value of the inflammatory indices i.e. Platelet Lymphocyte Ratio (PLR), Neutrophil Lymphocyte Ratio (NLR), and Systemic Immune Inflammation Index (SII) as potential predictors of Major Adverse Cardiovascular Event (MACE) in patients undergoing Primary Percutaneous Coronary Intervention (PPCI) on Saphenous Vein Graft (SVG) with a history of Coronary Artery Bypass Graft (CABG). This retrospective study evaluated 74 patients who underwent PPCI on SVG at a tertiary centre between 2015-2023. Patients were divided based on experiencing MACE within one year. Baseline characteristics and inflammatory markers were compared between groups. Logistic regression identified predictors of MACE. Of these 78, 74 completed the one-year follow-up and were included in the analysis. MACE occurred in 24 patients. We divided patients into two groups based on the occurrence of MACE. The MACE group had a significantly higher pre-procedural PLR compared to others (Mean difference [95%CI]: 22.24 [1.39, 42.23], p-value: 0.0346), while pre-procedural NLR, and SII, and post-procedural PLR, NLR, and SII were comparable between groups. Left Ventricular Ejection Fraction (LVEF) and pre-procedural PLR were predictors of one-year MACE; however, with low odds ratios (Odds Ratio [95%CI]: 0.91 [0.86, 0.96], 1.02 [1.00, 1.03], respectively). Only LVEF was an independent predictor of MACE. LVEF yielded a better discriminatory power than pre-procedural PLR. Pre-procedural PLR > 104.18 yielded a 70% sensitivity at 54% specificity for one-year MACE. Pre-procedural PLR and LVEF might be a predictor of one-year MACE following PPCI on SVG in post-CABG patients.
- 16 January 2025
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 80 (2) , 109-114
Predictive value of inflammatory indices for one year outcome of primary percutaneous coronary intervention on saphenous vein graft in post-coronary artery bypass grafting patients
This study aims to evaluate the prognostic value of the inflammatory indices i.e. Platelet Lymphocyte Ratio (PLR), Neutrophil Lymphocyte Ratio (NLR), and Systemic Immune Inflammation Index (SII) as potential predictors of Major Adverse Cardiovascular Event (MACE) in patients undergoing Primary Percutaneous Coronary Intervention (PPCI) on Saphenous Vein Graft (SVG) with a history of Coronary Artery Bypass Graft (CABG). This retrospective study evaluated 74 patients who underwent PPCI on SVG at a tertiary centre between 2015-2023. Patients were divided based on experiencing MACE within one year. Baseline characteristics and inflammatory markers were compared between groups. Logistic regression identified predictors of MACE. Of these 78, 74 completed the one-year follow-up and were included in the analysis. MACE occurred in 24 patients. We divided patients into two groups based on the occurrence of MACE. The MACE group had a significantly higher pre-procedural PLR compared to others (Mean difference [95%CI]: 22.24 [1.39, 42.23], p-value: 0.0346), while pre-procedural NLR, and SII, and post-procedural PLR, NLR, and SII were comparable between groups. Left Ventricular Ejection Fraction (LVEF) and pre-procedural PLR were predictors of one-year MACE; however, with low odds ratios (Odds Ratio [95%CI]: 0.91 [0.86, 0.96], 1.02 [1.00, 1.03], respectively). Only LVEF was an independent predictor of MACE. LVEF yielded a better discriminatory power than pre-procedural PLR. Pre-procedural PLR > 104.18 yielded a 70% sensitivity at 54% specificity for one-year MACE. Pre-procedural PLR and LVEF might be a predictor of one-year MACE following PPCI on SVG in post-CABG patients.
- 1 January 2023
- Published by Taylor & Francis in Future Cardiology
- Vol. 19 (1) , 19-27
The Outcome of ST-elevation Myocardial Infarction By Sex: A Retrospective Cohort Study
We aimed to compare in-hospital mortality (IHM) of acute myocardial infarction (AMI) between male and females. We assessed the association of sex with IHM after AMI using simple and multivariate co... Plain language summary What is this study about? Cardiovascular diseases are one of the leading causes of death and disability in both males and females worldwide. Over the few last decades, with t...
- 1 January 2023
- Published by Taylor & Francis in Future Cardiology
- Vol. 19 (1) , 19-27
The Outcome of ST-elevation Myocardial Infarction By Sex: A Retrospective Cohort Study
We aimed to compare in-hospital mortality (IHM) of acute myocardial infarction (AMI) between male and females. We assessed the association of sex with IHM after AMI using simple and multivariate co... Plain language summary What is this study about? Cardiovascular diseases are one of the leading causes of death and disability in both males and females worldwide. Over the few last decades, with t...